The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Monthly Belimumab Infusions Preserve Kidney Function in Some Lupus Patients

Monthly Belimumab Infusions Preserve Kidney Function in Some Lupus Patients

September 21, 2020 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters Health)—Intravenous belimumab combined with standard lupus therapy can help preserve kidney function in patients with active lupus nephritis and cut the odds of death or a renal-related event by half, a phase 3 multinational study has concluded.1

You Might Also Like
  • Subcutaneous Belimumab Improves Systemic Lupus Srythematosus Outcomes
  • Ixekizumab Promising for Non-Radiographic Axial SpA; Plus FDA Approves Belimumab for Pediatric Lupus
  • Antiplatelet Therapy May Protect Renal Function in Some Lupus Patients

After two years of therapy, 43% of 224 volunteers getting the drug monthly showed a renal response compared to 32% of the same number of patients receiving placebo (P=0.03).

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Thirty percent had a complete renal response vs. 20% with placebo (P=0.02). The difference was seen from the twelfth week onward.

A complete response was a ratio of urinary protein to creatinine of less than 0.5, an estimated glomerular filtration rate that was no worse than 10% below the value before a renal flare or at least 90 mL per minute per 1.73 square meters, and no use of rescue therapy. For a partial response, the urinary protein/creatinine had to be 0.7 or lower, the estimated glomerular filtration rate had to be no worse than 20% below the pre-flare value or at least 60 mL per minute or higher, and no rescue therapy.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Death or a renal-related event was seen in 35 of belimumab patients compared with 63 among placebo recipients (P=0.001).

The study was financed by GlaxoSmithKline, which helped collect, analyze and interpret the data.

“Most of the treatment effect was seen in patients who had received mycophenolate mofetil. No benefit was present in the subgroup of patients who received cyclophosphamide-azathioprine,” says Dr. Michael Ward and Dr. Maria Tektonidou in an editorial in The New England Journal of Medicine, where the study appears.2

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Induction treatment was not randomly assigned. “If patients with more severe nephritis were preferentially treated with cyclophosphamide, a likely inclination among most physicians, the trial may be telling us that belimumab enhances responses only among less severely affected patients,” writes Dr. Ward of the U.S. National Institutes of Health and Dr. Tektonidou of the National and Kopodistrian University in Athens.

They also note that the primary endpoint of the study, known as BLISS-LN, was changed in 2017, which was five years after the trial began.

Lupus nephritis becomes a problem in 25% to 60% of patients with systemic lupus erythematosus. In spite of treatment, 27% to 66% have flares of nephritis and 10% to 30% develop end-stage kidney disease.

The rate of serious adverse events was 26% with the drug and 30% with placebo. Treatment-related serious advents were seen in 10% and 11% respectively.

Pages: 1 2 | Single Page

Filed Under: Drug Updates Tagged With: belimumab, kidney, Lupus nephritis, SLE, systemic lupus erythematosus (SLE)

You Might Also Like:
  • Subcutaneous Belimumab Improves Systemic Lupus Srythematosus Outcomes
  • Ixekizumab Promising for Non-Radiographic Axial SpA; Plus FDA Approves Belimumab for Pediatric Lupus
  • Antiplatelet Therapy May Protect Renal Function in Some Lupus Patients
  • Oxycodone Capsules Put on Hold; Clinical Trials for Lupus Nephritis & SLE Therapies

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)